Novo Nordisk confident of amycretin obesity drug launch this decade
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK1,054 at TD Cowen
March 11, 2024 2:03 PM EDTTD Cowen analyst Steve Scala raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,054.00 (from DKK925.00) while maintaining a Outperform rating.
The analyst comments "Novo announced FDA approval of the expanded label for Wegovy, now indicated to reduce CV risk in people with both obesity and CVD based on data from SELECT. Though these data are widely appreciated by specialists after... More
